Cloud DX announced that on February 6th, 2024 it received a purchase order (PO) for up to 300 advanced Vitaliti? Continuous Vital Sign Monitor Systems and related software, valued at approximately $770,000. As of September 30, 2023 Cloud DX reported gross margins of approximately 77%.

The units will be manufactured at the Company's Kitchener ON facility and are expected to be delivered by the end of Second Quarter 2024. The PO specifies a 50% deposit with the balance to be paid upon delivery. These patented and patent pending Vitaliti units are expected to be deployed in multi-site studies of post-operative patients, with the first conducted under a Health Canada ITA in advance of full Health Canada license and FDA clearance.

Patients will be followed at home after surgery, and Vitaliti data will be used to train generative artificial intelligence (AI) algorithms that are expected to predict and avoid adverse healthcare outcomes. Vitaliti is the subject of peer-reviewed academic papers, demonstrating the system's accuracy when measuring continuous non-invasive blood pressure, and its competitive place in the continuous multi-parameter monitoring landscape, respectively, including: "Continuous Noninvasive Remote Automated Blood Pressure Monitoring with Novel Wearable Technology: A Preliminary Validation Study", JMIR mHealth and uHealth, Vol 10, No 2 (February 2022) and "Beyond Wellness Monitoring: Continuous Multiparameter Remote Automated Monitoring of Patients", Canadian Journal of Cardiology, Volume 38, Issue 2, P267-278, February 2022. Vitaliti Facts: Each light weight Vitaliti system consists of a main unit that attaches to the chest, ECG leads and an advanced earpiece with multiple sensors for heart rate, pulse oxygen and temperature; up to 72 hours of continuous use; advanced 2-lead ECG with 3 additional leads for full 5-lead ECG data; continuous non-invasive blood Pressure without a cuff; pulse oxygen, heart rate, respiration rate, core body temperature and 3-axis accelerometer and gyroscope data; and generative AI algorithms that can detect cardiac anomalies, atrial fibrillation and predict negative health outcomes in time for clinicians to intervene.

Vitaliti is designed to complement the best-in-class Cloud DX Connected Health kits now used for periodic monitoring of vital signs and comprehensive virtual care across North America. So far in 2024, Cloud DX has announced 7 contracts/orders valued in excess of $2.5 million CAD, including with Health PEI, Markham Stouffville Hospital and VHA Home HealthCare. Cloud DX CEO and Founder Robert Kaul stated.

" This initial order for advanced Vitaliti CVSM systems is an important milestone for Cloud DX. The company first introduced Vitaliti as the core element of XPRIZE-winning Tricorder in 2017. The company then went back to a clean sheet of paper and re-designed Vitaliti to become one of the most accurate and effective continuous vital sign monitor solutions in the world.

This first deployment of Vitaliti in a highly-regarded, multi-site, multi-year clinical study will move forward the state of the art in virtual care while also gathering data required for Health Canada and FDA regulatory approvals.